TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04134260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormone Therapy
Description: Receive hormone therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormone Therapy
Description: Receive hormone therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo pelvis and prostate bed radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo pelvis and prostate bed radiation therapy
Study: NCT04312802

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test (CPET)
Description: The participant will undergo a cardio-pulmonary exercise test (CPET) on a cycle ergometer (Ergoline) connected to a 12-lead electrocardiogram, oxygen saturation monitor and continuous non-invasive blood pressure cuff. Respiratory gas exchanged will be measured from a tight fitting facemask. An initial 2-min period of baseline data will be collected at rest before a 180-s period of unloaded cycling. A ramp protocol will then be applied and the participant will be instructed to continue cycling at a constant cadence of 60 rpm as long as they can. The test will be terminated if the participant indicates that:~* they cannot continue~* cadence falls to \<55 rpm due to fatigue or dyspnoea~* they develop abnormal cardiac signs or symptoms, such as ischaemia and arrhythmia.
Study: NCT04062305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand Function Test
Description: Complete tasks that test grip strength, pinch strength, and ability to use and feel with hands

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Navigated Transcranial Magnetic Stimulation
Description: Undergo nTMS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03175029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAC-302
Description: TAC-302 200 mg administered orally twice per day after meals, for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally twice per day after meals, for 12 weeks.
Study: NCT03381183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Phase 1 and Phase 2: 1500 mg every 4 weeks (Q4wks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Phase 1 and Phase 2: 1500 mg every 4 weeks (Q4wks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRX-2 Regimen
Description: Phase 1 and Phase 2 - Every 12 weeks - IRX-2 Regimen:~Cyclophosphamide 300 mg/m\^2 - intravenously.~IRX-2: 460 units daily (4 injections of 115 units).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRX-2 Regimen
Description: Phase 1 and Phase 2 - Every 12 weeks - IRX-2 Regimen:~Cyclophosphamide 300 mg/m\^2 - intravenously.~IRX-2: 460 units daily (4 injections of 115 units).
Study: NCT04089371

Intervention type: DEVICE
Intervention: ReUnion Total Shoulder Arthroplasty (TSA)
Description: The ReUnion RFX System includes a Reversible Fracture Stem (RFX Stem) that can utilize either the ReUnion Total Shoulder Arthroplasty (TSA) or ReUnion Reverse Shoulder Arthroplasty (RSA) humeral and glenoid components and is indicated for use as a hemi, total or reverse shoulder replacement. The ReUnion RFX stem is intended for cemented use only.

Intervention type: DEVICE
Intervention: ReUnion Reverse Shoulder Arthroplasty (RSA)
Description: The ReUnion RFX System includes a Reversible Fracture Stem (RFX Stem) that can utilize either the ReUnion Total Shoulder Arthroplasty (TSA) or ReUnion Reverse Shoulder Arthroplasty (RSA) humeral and glenoid components and is indicated for use as a hemi, total or reverse shoulder replacement. The ReUnion RFX stem is intended for cemented use only.
Study: NCT04197921

Intervention type: DEVICE
Group type: OTHER
Intervention: Exablate Model 4000 Type 2.0/2.1
Description: There are two treatment stages. In both stages, the subject will receive both the sham and active ExAblate treatment, and be evaluated for 90 days post-treatment for adverse events. During Stage 1 the subject will receive the moderate intensity Exablate LIFU procedure. During Stage2, the subject will receive the enhanced intensity ExAblate LIFU procedure. The subjects are blinded as to the order of the sham vs active treatment.
Study: NCT02312557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT05838183

Intervention type: DIAGNOSTIC_TEST
Intervention: The relationship between imaging and ROSE and NGS
Description: The correlation between ROSE and NGS in imaging and bronchoscopy of ILD patients was observed

Intervention type: DIAGNOSTIC_TEST
Intervention: The relationship between imaging and ROSE and NGS
Description: The correlation between ROSE and NGS in imaging and bronchoscopy of ILD patients was observed
Study: NCT04535544

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JNJ-73763989
Description: JNJ-73763989 will be administered as a SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 will be administered as a SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to JNJ-73763989 will be administered as a SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entecavir (ETV) monohydrate
Description: ETV monohydrate film coated tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) monohydrate
Description: ETV monohydrate film coated tablet will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir disoproxil
Description: Tenofovir disoproxil film-coated tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil
Description: Tenofovir disoproxil film-coated tablet will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir alafenamide (TAF)
Description: TAF film coated tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF)
Description: TAF film coated tablet will be administered orally.
Study: NCT02609386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Method of Administration: Indomethacin is administered orally for 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: Method of Administration: Indomethacin is administered orally for 21 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc-containing multivitamin
Description: Method of Administration: Zinc-containing multivitamin is administered orally for 21 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc-containing multivitamin
Description: Method of Administration: Zinc-containing multivitamin is administered orally for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Method of Administration: Omeprazole is administered orally for 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Method of Administration: Omeprazole is administered orally for 21 days
Study: NCT04378595

Intervention type: OTHER
Intervention: During COVID-19 Pandemic
Description: Assessing status of food insecurity during the COVID-19 pandemic

Intervention type: OTHER
Intervention: After COVID-19 Pandemic
Description: Assessing status of food insecurity after the COVID-19 pandemic
Study: NCT02029482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-128800

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04630782

Intervention type: DIAGNOSTIC_TEST
Intervention: PET-MRI scan
Description: Participants will be scanned centrally at Clinical Imaging Research Centre (CIRC, Singapore), on a Biograph mMR PET-MR scanner. Combined FDG-PET-MRI scan is critical for co-registration of peristaltic bowel for optimal image quality. The oesophagus to anorectum will be imaged. The PET-MRI scan starts 60 minutes post-FDG injection of 6mCi and immediately after injecting 10mg hyoscine butylbromide to reduce peristalsis. MRI sequences are non-contrast.

Intervention type: DIAGNOSTIC_TEST
Intervention: PET-MRI scan
Description: Participants will be scanned centrally at Clinical Imaging Research Centre (CIRC, Singapore), on a Biograph mMR PET-MR scanner. Combined FDG-PET-MRI scan is critical for co-registration of peristaltic bowel for optimal image quality. The oesophagus to anorectum will be imaged. The PET-MRI scan starts 60 minutes post-FDG injection of 6mCi and immediately after injecting 10mg hyoscine butylbromide to reduce peristalsis. MRI sequences are non-contrast.

Intervention type: DIAGNOSTIC_TEST
Intervention: PET-MRI scan
Description: Participants will be scanned centrally at Clinical Imaging Research Centre (CIRC, Singapore), on a Biograph mMR PET-MR scanner. Combined FDG-PET-MRI scan is critical for co-registration of peristaltic bowel for optimal image quality. The oesophagus to anorectum will be imaged. The PET-MRI scan starts 60 minutes post-FDG injection of 6mCi and immediately after injecting 10mg hyoscine butylbromide to reduce peristalsis. MRI sequences are non-contrast.
Study: NCT02624635

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: The scheme established for that intervention is as follows: joint manipulation passive ankle and foot, myofascial release technique (gastrocnemius, soleus muscle and plantar fascia), neural mobilization (nerve tibial) and stretching the plantar region and sural triceps, following the recommendations described by Mcpoil et al. (2008).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy and Hip Strengthening
Description: It will be done the same treatment performed in group 1 plus the strengthening of the muscles of the hip (iliac muscle, psoas, gluteus maximus, gluteus medius and gluteus minimus) and the treatment schedule established for this intervention is the use of exercises with progressive resistance. Will be performed 3 sets of 10 reps with 30 seconds rest between each set, according to the guidelines of the American College of Sports Medicine (ACSM, 2014). The home exercises consist of repeating the same procedures performed for supervised strengthening. The calculation of the ideal individual load will be carried by Brzycki formula, i.e. one repetition maximum (1RM) = weight ÷ \[1.0278 - (0.0278 x number of repetitions)\] as was used by (Shirazi et al., 2007).
Study: NCT03405168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Hydrochloride 400mg Tablet
Description: Moxifloxacin is oral administration, 400 mg once a day, D1 to D7, 28 days as one cycle.
Study: NCT02640898

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: docetaxel-based chemoradiotherapy
Description: experimental:Patients with Zubrod performance status (PS) of 0-2 received up to 2 21-day cycles of pre- and post-radiation chemotherapy (docetaxel 37.5 mg/m2 on days 1 and 8, cisplatin 25 mg/m2 on days 1-3, and a continuous infusion of fluorouracil (FU) 750 mg/m2 on days 1-5), respectively. CCRT between pre- and post-radiation chemotherapy was initiated on day 43 and consisted of 3-dimensional conformal intensity-modulated radiation therapy (45 Gy) plus concurrent docetaxel 20 mg/m2 weekly for 6 weeks;

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: FU-based chemoradiotherapy
Description: The adjuvant treatment consisted of 425mg/m2 of bolus fluorouracil(5-FU) per day, 20 mg/m2 of leucovorin (LV), per day, for 5 days, followed by 45Gy of radiation with current 5-FU ( 400mg/m2 ) and LV (20mg/m2) as an intravenous bolus on each of of the first four days and the last three days of irradiation. One month after the completion of radiotherapy, two 5-day cycles of 5-FU and FV chemotherapy were given one month apart.
Study: NCT00459771

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AT1 blocker candesartan
Description: AT1 blocker candesartan, 32 mg oral QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 32 mg, oral QD
Study: NCT03594799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bed Rest Control Group
Description: Subjects are in strict head down tilt bed rest at all time (including for taking showers etc.) for 60 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cocktail intervention
Description: Subjects are in strict head down tilt bed rest at all time (including for taking showers etc.) for 60 days. In addition subjects are receiving a daily supplementation of a Cocktail. The daily dose of Cocktail consists of 6 pills per day: 2 at breakfast, 2 at lunch and 2 at diner. This will be equivalent to a daily dose of around 741 mg of bioactive polyphenols associated with Omega-3, Selenium and Vitamine E.
Study: NCT03019029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18-F Florbetapir PET/MR scan
Description: 18-F Florbetapir PET/MR scan, PET/MR on a GE SIGNA PET/MR scanner
Study: NCT02131233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reformulated Raltegravir
Description: Reformulated raltegravir 1200 mg (2x 600 mg tablets) orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: Raltegravir 400 mg tablet orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRUVADA™
Description: Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRUVADA™
Description: Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Reformulated Raltegravir
Description: Placebo to reformulated raltegravir 2 tablets orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Raltegravir
Description: Placebo to raltegravir 1 tablet orally twice daily
Study: NCT01818089

Intervention type: DEVICE
Intervention: Lung sound analyzer
Description: Patients will be aucultated with lung sound analyzer. The auscultation will be done three times daily during the duration of the complete hospital stay.
Study: NCT02535650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Tipifarnib will be administered at a starting dose of 900 mg, po, bid on days 1-7 and 15-21 of 28-day treatment cycles. In the absence of unmanageable toxicities, subjects may continue to receive tipifarnib treatment for up to 12 months as long as the Investigator considers that the treatment is providing clinical benefit.
Study: NCT01869088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Adenovirus Type 5 Injection
Description: After identifying the target artery of HCC, Recombinant Human Adenovirus Type 5 Injection（15.0\*1011vp：0.5ml\*3） will be first infused through the target artery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transartery Chemoembolization
Description: Transartery chemoembolization with chemothrapy drugs (E-ADM 50mg, Lobaplatin 50 mg, MMC 6mg)and followed with embolization with lipiodol or/and polyvinyl alcohol particles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transartery Chemoembolization
Description: Transartery chemoembolization with chemothrapy drugs (E-ADM 50mg, Lobaplatin 50 mg, MMC 6mg)and followed with embolization with lipiodol or/and polyvinyl alcohol particles.
Study: NCT00383370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEGF Trap
Description: VEGF Trap formulation 1, ITV-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEGF Trap
Description: VEGF Trap formulation 1, ITV-1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGF Trap
Description: VEGF Trap formulation 2 at higher concentration in Open label cohort
Study: NCT02957617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074
Description: Participants will receive an initial dose regimen of 350mg orally twice daily (BID), which may be reduced to 200mg based on tolerability for up to 12 months.
Study: NCT00817388

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03147950

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prone-Flexed PCNL
Description: Prone-Flexed Position For Percutaneous Nephrolithotomy (PCNL)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prone PCNL
Description: Prone Position For Percutaneous Nephrolithotomy (PCNL)
Study: NCT03301077

Intervention type: OTHER
Intervention: 2-phase epidemiological study (screening, interviews)
Description: first phase is the screening phase, second phase is the interview phase
Study: NCT02149563

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: oxygen-enriched air -Normobaric hyperoxia treatment for depression
Description: Forty percent oxygen or regular air will be supplied from oxygen concentrators, through standard plastic nasal prongs, at a flow rate of 5 liters/minute, for 7 hours a day, throughout the night.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: oxygen-enriched air -Normobaric hyperoxia treatment for depression
Description: Forty percent oxygen or regular air will be supplied from oxygen concentrators, through standard plastic nasal prongs, at a flow rate of 5 liters/minute, for 7 hours a day, throughout the night.
Study: NCT01825746

Intervention type: OTHER
Group type: OTHER
Intervention: Implementation of the MOHR assessment in primary care workflow
Description: The MOHR assessment includes (1) asking patients to complete the MOHR assessment on the web prior to encounters (available at www.MyOwnHealthReport.org it addresses10 distinct health behaviors and psychosocial issues including physical activity, diet, alcohol consumption, tobacco use, drug use, sleep, stress, depression and anxiety), (2) provision, via the tool, immediate patient feedback that includes identification of unhealthy issues, assessment of readiness to change, prioritization of issues to change, and preparation for goal-setting and action planning, (3) feedback to the primary care team on the patient status and priorities for change, (4) provision of counseling, goal setting, and referrals to local resources by clinicians during the subsequent office visit, and (5) follow-up with the clinicians and local resources as agreed upon by the patient and clinician.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implementation of the MOHR assessment in primary care workflow
Description: The MOHR assessment includes (1) asking patients to complete the MOHR assessment on the web prior to encounters (available at www.MyOwnHealthReport.org it addresses10 distinct health behaviors and psychosocial issues including physical activity, diet, alcohol consumption, tobacco use, drug use, sleep, stress, depression and anxiety), (2) provision, via the tool, immediate patient feedback that includes identification of unhealthy issues, assessment of readiness to change, prioritization of issues to change, and preparation for goal-setting and action planning, (3) feedback to the primary care team on the patient status and priorities for change, (4) provision of counseling, goal setting, and referrals to local resources by clinicians during the subsequent office visit, and (5) follow-up with the clinicians and local resources as agreed upon by the patient and clinician.
Study: NCT02710019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Back to Reality Series Video Games
Description: Back to Reality Series are a psycho-educational video games that provide information about psychosis and marijuana use from the perspective of 'Harry': a character who experiences problems with both issues. The aim is for players to learn how to detect some signs of psychosis and where to seek help for mental health and addictions problems.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Video Game
Description: The control video game consists of digital puzzles and spelling game about pop culture. The control games does not have any content related to mental health and addictions problems
Study: NCT02311608

Intervention type: DRUG
Intervention: Terlipressin
Description: administered as a first-line medicine or as salvage

Intervention type: DRUG
Intervention: Terlipressin
Description: administered as a first-line medicine or as salvage

Intervention type: DRUG
Intervention: Terlipressin
Description: administered as a first-line medicine or as salvage

Intervention type: DRUG
Intervention: Usual Dose Somatostatin/Octreotide
Description: administered as a first-line medicine or as salvage

Intervention type: DRUG
Intervention: Usual Dose Somatostatin/Octreotide
Description: administered as a first-line medicine or as salvage

Intervention type: DRUG
Intervention: Usual Dose Somatostatin/Octreotide
Description: administered as a first-line medicine or as salvage

Intervention type: DRUG
Intervention: Usual Dose Somatostatin/Octreotide
Description: administered as a first-line medicine or as salvage

Intervention type: DRUG
Intervention: High Dose Somatostatin/Octreotide
Description: administered as salvage

Intervention type: DRUG
Intervention: High Dose Somatostatin/Octreotide
Description: administered as salvage
Study: NCT02117609

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: New DELICAL formula
Description: 3 months with the option of continuing until 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard DELICAL formula
Description: 3 months with the option of continuing until 6 months.
Study: NCT00177866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celebrex
Description: Celebrex 200 mg PO BID for the first 8 weeks, followed by a 1 week washout period then placebo PO BID for the remaining 8 weeks - or - placebo PO BID for the first 8 weeks, followed by a 1 week washout period then Celebrex 200 mg PO BID for the remaining 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo PO BID for either the first eight weeks or the last eight weeks of the study.